|
|
CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C |
Approved |
|
GABAA receptors
|
Unknown,
GABA A receptor binding,
Muscarinic receptor binding
|
|
|
|
C1=CC(=CC=C1N)S(=O)(=O)N |
not approved |
|
LUX (GENE)
|
Affects flowering rhythms (LUX)
|
|
|
|
CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O |
Approved |
|
Microbiota
|
Unknown
|
|
|
|
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl |
Approved |
|
D2R (dopamine receptor)
|
Dopamine receptor binding
|
|
|
|
C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-] |
Approved |
|
Mitochondrial translation machine
|
Chloramphenicol can inhibit both bacterial and mitochondrial protein synthesis
|
|
|
|
C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C |
Approved |
|
organellar transcription
|
Lenghthen the circadian period
|
|
|
|
C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO |
Approved |
|
Unknown
|
Unknown
|
|
|
|
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl |
Approved |
|
NPAS2
|
Unknown
|
|
|
|
CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl |
Approved |
|
D2R (dopamine receptor)
|
Dopamine receptor binding
|
|
|
|
C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F |
Approved |
|
D2R (dopamine receptor)
|
Dopamine receptor binding,
Dopamine receptor agonist
|
|
|
|
CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24 |
Approved |
|
5-HT7
|
5-HT7 binding
|
|
|
|
C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1 |
None |
|
mPer2
,
mPer1
,
CRY1-PER2 complex
,
CRY1
,
CLOCK-BMAL1
|
Disruption of circadian clock,
Bmal1,
Interferes with CLOCK–BMAL1,
Targets BMAL1–CLOCK DNA-binding activity,
aryl hydrocarbon receptor (AhR) binding
|
|
|
|
COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC |
Approved |
|
CLOCK-BMAL1
,
BMAL1 expression (induction)
,
JAK2
,
EGFR
|
inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase
|
|
|
|
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C |
Approved |
|
Unknown
|
Disruption of circadian clock,
Unknown
|
|
|
|
CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F |
Approved |
|
Unknown
|
Binding to rat brainα- andβ-adrenergic, muscarinic cholinergic, dopamine and opiate receptors
|
|
|
|
CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC |
Approved |
|
D2R (dopamine receptor)
|
Dopamine receptor binding
|
|
|
|
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4C5=C(C=C(C=C5)F)ON4 |
Approved |
|
mPer2
,
mPer1
,
CRY1-PER2 complex
,
CRY1
,
CRY1
,
REV-ERBα
|
Core clock modulation,
PER gene exspression modulation,
CRY gene expression modulation,
BMAL1 expression modulation
|
|
|
|
CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O |
Approved |
|
CLOCK-BMAL1
,
Arntl (gene)
,
BMAL1 expression (induction)
|
Bmal1,
de-repressing BMAL1,
BMAL1 expression modulation,
BMAL1 expression modulation
|
|
|
|
CC1=NC(=NC=C1OC[C@]2(C[C@H]2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F |
Approved |
|
Orexin Receptors OX1R and OX2R
|
Orexin Receptor Antagonism
|
|
|
|
C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl |
Approved |
|
Histamine 1 receptor
|
Histamine 1 blocker
|
|
|
|
C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F |
Approved |
|
D2R (dopamine receptor)
|
Dopamine receptor binding,
Dopamine receptor binding,
Dopamine receptor antagonist
|
|
|
|
CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C |
Approved |
|
GABAA receptors
|
Hypnotic effect,
GABAergic system influence
|
|
|
|
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC |
Approved |
|
Mu opioid receptor
,
OPRK1
,
OPRD1
|
Unknown,
Mu opioid receptor binding,
Kappa opioid receptor binding,
delta opioid receptor binding
|
|
|
|
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C |
Approved |
|
Histamine 1 receptor
|
Histamine 1 blocker
|
|
|
|
CC1CCC(CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F |
Not approved |
|
Orexin Receptors OX1R and OX2R
|
Orexin Receptor Antagonism
|
|